Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Avelumab Demonstrates Favorable Activity in Gestational Trophoblastic Tumors

September 3rd 2020

Benoit You, MD, PhD, discusses the need for novel and well-tolerated agents in chemotherapy-resistant gestational trophoblastic tumors and ongoing research efforts designed to bring avelumab to the forefront of the treatment paradigm.

Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer

September 3rd 2020

In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

Surgery-Free Alternative Is Favorably Accepted Among Women at Risk of Ovarian Cancer

August 26th 2020

The majority of women at a high risk of developing ovarian cancer reported having a favorable attitude toward adopting a two-step risk-reducing early salpingectomy and delayed oophorectomy instead of a risk-reducing salpingo-oophorectomy.

Trastuzumab Duocarmazine Under Exploration in HER2+ Endometrial Cancer

August 25th 2020

Investigators are evaluating the safety and efficacy of the investigational antibody-drug conjugate vic-trastuzumab duocarmazine in patients with HER2-expressing recurrent, advanced, or metastatic endometrial cancer in the phase 2 SYD985.003 trial.

Moore Highlights Hope for Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

August 25th 2020

In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.

Dr. Liu on Cediranib/Olaparib in Recurrent Ovarian Cancer

August 14th 2020

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

August 13th 2020

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Phase 3 OVAL Trial With VB-111 in Platinum-Resistant Ovarian Cancer to Continue

August 12th 2020

The independent data safety monitoring committee has unanimously recommended that the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer continue as planned.

Dr. Monk on Emerging Therapies in Cervical Cancer

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

Dr. Westin on Challenges With Precision Medicine in Endometrial Cancer

August 4th 2020

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer.

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 3rd 2020

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Blood Spectroscopy Could Detect Early Endometrial Cancer Diagnoses

July 30th 2020

Blood spectroscopy testing could be a faster, more accurate, less-invasive, and more cost-effective method for testing and diagnosing women with the early stages of endometrial cancer.

Monk Magnifies Emerging Approaches Making Headway in Cervical Cancer Management

July 29th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses key updates in cervical cancer treatment, exciting ongoing research efforts, and emerging approaches that are shaking up the treatment paradigm.

Dr. Monk on the Importance of Early Pap Testing in Cervical Cancer

July 27th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of Pap testing early on in cervical cancer.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

ATHENA Trial of Maintenance Rucaparib/Nivolumab in Ovarian Cancer Completes Target Enrollment

July 23rd 2020

The pivotal phase 3 ATHENA trial, which will examine the safety and efficacy of rucaparib in combination with nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, has completed target enrollment.

USC73 Score Predictive of OS in Uterine Serous Carcinoma

July 23rd 2020

A 73-gene proliferative transcriptomic signature was found to better predict overall survival outcomes and potentially be used to personalize treatment in patients with uterine serous carcinoma.

Dr. Slomovitz on the Role of Surgery in Endometrial Cancer

July 15th 2020

Brian M. Slomovitz, MD, discusses the role of surgery in women with endometrial cancer.